TTN-, BAG3-, and MYH7-associated DCMs follow a less arrhythmogenic and more heart failure-prone clinical course.21,23,27 The management of mild forms of TTN-, BAG3-, and MYH7-associated DCM follows the regular treatment for patients with heart failure,56 whereas the detection of a genetic variant in a pro-arrhythmogenic gene requires an increase in arrhythmia monitoring independent of LVEF values. This evidence concerns the gene BAG3 and heart failure.